441 related articles for article (PubMed ID: 17202400)
1. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
Greene LM; Kelly L; Onnis V; Campiani G; Lawler M; Williams DC; Zisterer DM
J Pharmacol Exp Ther; 2007 Apr; 321(1):288-97. PubMed ID: 17202400
[TBL] [Abstract][Full Text] [Related]
2. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
[TBL] [Abstract][Full Text] [Related]
3. Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment.
Bright SA; Campiani G; Deininger MW; Lawler M; Williams DC; Zisterer DM
Biochem Pharmacol; 2010 Jul; 80(1):31-8. PubMed ID: 20206141
[TBL] [Abstract][Full Text] [Related]
4. Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl.
Mc Gee MM; Campiani G; Ramunno A; Fattorusso C; Nacci V; Lawler M; Williams DC; Zisterer DM
J Pharmacol Exp Ther; 2001 Jan; 296(1):31-40. PubMed ID: 11123359
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
7. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
8. Selective induction of apoptosis by the pyrrolo-1,5-benzoxazepine 7-[[dimethylcarbamoyl]oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia cells occurs via the c-Jun NH2-terminal kinase-dependent phosphorylation and inactivation of Bcl-2 and Bcl-XL.
Mc Gee MM; Greene LM; Ledwidge S; Campiani G; Nacci V; Lawler M; Williams DC; Zisterer DM
J Pharmacol Exp Ther; 2004 Sep; 310(3):1084-95. PubMed ID: 15143129
[TBL] [Abstract][Full Text] [Related]
9. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
[TBL] [Abstract][Full Text] [Related]
13. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
15. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
Yu C; Krystal G; Dent P; Grant S
Clin Cancer Res; 2002 Sep; 8(9):2976-84. PubMed ID: 12231544
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
17. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
18. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
19. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.
Rakshit S; Bagchi J; Mandal L; Paul K; Ganguly D; Bhattacharjee S; Ghosh M; Biswas N; Chaudhuri U; Bandyopadhyay S
Apoptosis; 2009 Mar; 14(3):298-308. PubMed ID: 19153832
[TBL] [Abstract][Full Text] [Related]
20. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
Lothstein L; Savranskaya L; Sweatman TW
Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
